The latest market report published by Credence Research, Inc. “Freezing of Gait Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2019 – 2027” the freezing of gait treatment market expected to grow at a CAGR of 7.2% during the forecast period from 2019 to 2027.
The global freezing of gait treatment market is growing effectively from 2019 to 2027 accredited to the rise in admissions for PD related patients in clinics and hospitals along with improved medical care infrastructure on a global scale. Approval for new medications and therapies along with equipment and implants in the pipeline, technology expansion in wearable and walking aid devices is driving the overall market growth. The effective management of neuroprotective therapy along with pharmacologic treatment of PD will gain traction slowly in the international market. Patient’s dealing with Freezing of gait note that their feet feel stuck to the ground and it may lead to lead to imbalance and falls such as fractures and hospital admissions. Freezing of gait can frequently be triggered by cognitive influences such as anxiety or distraction, or while passing through the doorways, lifts, busy crowds or tight spaces.
Research and development for top quality medications with increased cost in the end user segment are driving the overall growth. Freezing of gait patients is greatly helped by levodopa/carbidopa. However, medications and therapies or exercises does not fully eliminate the symptoms. Deep brain stimulation procedures are also adopted in few of the cases. In Dec 2017, researchers from NUI Galway discovered a new device named ‘cueStim’, intended to help those living with freezing of gait. It can electrically stimulate the changes in the human body and can be controlled by Bluetooth or a smartphone-enabled device.
Top drug and equipment manufacturers are mainly focusing on new product launch and FDA approval. The rising number of partnerships with research centers and strategic alliance by key players internationally will drive the market growth in the near future. For instance, in Dec 2018, Acorda Therapeutics, Inc. announced the FDA approval of INBRIJA™, inhaled Levodopa for on-demand use for OFF periods in people with Parkinson’s disease taking levodopa/carbidopa. Nevertheless, the high cost of treatment, the burden of PD with very fewer treatment options globally, less awareness related to pipeline products and less favorable outcomes after a long duration of the treatment life cycle are few factors restraining the growth of the freezing of gait treatment market on a global scale.
Key Market Movements:
• Globally, the freezing of gait treatment is growing at a CAGR of 7.2% for the period from 2019 to 2027
• The U.S. market will gain traction due to its improved infrastructure, large PD patient pool and FDA approval for new medications
• Growing number of hospitals and clinics, strong pipeline products for freezing of gait treatment, and increased medical care expenditure in the emerging nations will drive the overall market growth
• Major players in this vertical are Acorda Therapeutics, The Michael J. Fox Foundation, GYENNO, National University of Ireland Galway (NUI Galway), Kyungpook National University Republic of Korea, MedEXO Robotics, Teva Pharmaceuticals and others
Browse full report at https://www.credenceresearch.com/report/freezing-of-gait-treatment-market
The Global Freezing of Gait Treatment Market is Segmented into:
|Segmentation||By Position (2019–2027; US$ Mn)|
|By Type of Fog Lights (2019–2027; US$ Mn)|
|By Color Type (2019–2027; US$ Mn)|
|By Channel (2019–2027; US$ Mn)|
|By Vehicle (2019–2027; US$ Mn)|
|By Geography Segment (2019–2027; US$ Mn)|
*Complete segmentation list is on report page